Paediatric Haematology Research Unit
51 – 100 of 264
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Endovascular treatment of vein of Galen aneurysmal malformation using rapid ventricular pacing : A case report
(
- Contribution to journal › Article
-
Mark
Plasma products do not solve the inhibitor problem
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Outcome measures for adult and pediatric hemophilia patients with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
The care of a child with a newly diagnosed immune thrombocytopenia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B
(
- Contribution to journal › Article
-
Mark
Ataxia-pancytopenia syndrome with SAMD9L mutations
(
- Contribution to journal › Article
-
Mark
Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
(
- Contribution to journal › Article
-
Mark
Effect of late prophylaxis in hemophilia on joint status : A randomized trial
(
- Contribution to journal › Article
- 2016
-
Mark
Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.
2016) In Haemophilia(
- Contribution to journal › Article
-
Mark
Origin of mutation in sporadic cases of severe haemophilia A in Sweden.
(
- Contribution to journal › Article
-
Mark
Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia - a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.
(
- Contribution to journal › Article
-
Mark
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels.
(
- Contribution to journal › Scientific review
-
Mark
BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
(
- Contribution to journal › Article
-
Mark
Inhibitor development in previously untreated patients with severe haemophilia A : a nationwide multicentre study in Finland
(
- Contribution to journal › Article
-
Mark
Phenotype and genotype comparisons in carriers of haemophilia A
(
- Contribution to journal › Article
-
Mark
Pain and pain management in haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors
(
- Contribution to journal › Article
-
Mark
Aspects of prophylactic treatment of hemophilia
(
- Contribution to journal › Scientific review
-
Mark
Breath-holding spells occur disproportionately more often in children with transient erythroblastopenia
(
- Contribution to journal › Article
-
Mark
Potential biomarkers of haemophilic arthropathy : correlations with compatible additive magnetic resonance imaging scores
(
- Contribution to journal › Article
- 2015
-
Mark
Tailoring care to haemophilia patients' needs: which specialty and when?
(
- Contribution to journal › Article
-
Mark
Various regimens for prophylactic treatment of patients with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Can a "center effect" explain the higher frequency of inhibitors for a second generation recombinant factor VIII product?
(
- Contribution to journal › Letter
-
Mark
The current status of prophylactic replacement therapy in children and adults with haemophilia.
(
- Contribution to journal › Scientific review
-
Mark
Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.
(
- Contribution to journal › Letter
-
Mark
How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access
(
- Contribution to journal › Article
-
Mark
Rationale for individualizing haemophilia care.
(
- Contribution to journal › Scientific review
-
Mark
Switching treatments in haemophilia: is there a risk of inhibitor development?
(
- Contribution to journal › Scientific review
-
Mark
Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations.
2015) In Haemophilia(
- Contribution to journal › Article
-
Mark
Hematologi
2015) p.237-246(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2014
-
Mark
Definitions in hemophilia: communication from the SSC of the ISTH
(
- Contribution to journal › Article
-
Mark
Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B.
(
- Contribution to journal › Article
-
Mark
Prenatal diagnosis of haemophilia in Sweden now more commonly used for psychological preparation than termination of pregnancy.
(
- Contribution to journal › Article
-
Mark
Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
(
- Contribution to journal › Scientific review
-
Mark
Factor VIII therapy for hemophilia A: current and future issues
(
- Contribution to journal › Scientific review
-
Mark
Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry
(
- Contribution to journal › Article
-
Mark
Perinatal aspects of haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Similar bleeding phenotype in young children with haemophilia A or B : A cohort study
(
- Contribution to journal › Article
-
Mark
Textbook of hemophilia : Care of the child with hemophilia
2014) p.145-150(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2013
-
Mark
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
(
- Contribution to journal › Article
-
Mark
Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.
(
- Contribution to journal › Scientific review
-
Mark
40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics, and preliminary efficacy in hemophilia patients with inhibitors.
(
- Contribution to journal › Article
-
Mark
Increased burden on caregivers of having a child with haemophilia complicated by inhibitors.
2013) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
Origin of Swedish hemophilia B mutations
(
- Contribution to journal › Article
-
Mark
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
(
- Contribution to journal › Article
-
Mark
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
(
- Contribution to journal › Article
-
Mark
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Hemophilia and prophylaxis.
(
- Contribution to journal › Scientific review
- 2012
-
Mark
Beyond patient benefit: clinical development in hemophilia
(
- Contribution to journal › Scientific review
-
Mark
Haemophilia Care in Europe: the ESCHQoL study
(
- Contribution to journal › Article